{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:37:08Z","timestamp":1784806628039,"version":"3.55.0"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T00:00:00Z","timestamp":1762732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Arch Virol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s00705-025-06419-x","type":"journal-article","created":{"date-parts":[[2025,11,10]],"date-time":"2025-11-10T08:20:08Z","timestamp":1762762808000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["A virus-like-particle-producing DNA vaccine triggers specific humoral immunity against hepatitis C virus in mice"],"prefix":"10.1007","volume":"170","author":[{"given":"Nahla A.","family":"Hussein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rasha A. M.","family":"Azouz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reem","family":"El-Shenawy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naiera M.","family":"Helmy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashraf A.","family":"Tabll","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasmine S.","family":"El-Abd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7864-8240","authenticated-orcid":false,"given":"Ahmed A.","family":"Ali","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,11,10]]},"reference":[{"key":"6419_CR1","volume-title":"WHO Hepatitis C Key Facts","author":"WHO","year":"2024","unstructured":"WHO (2024) WHO Hepatitis C Key Facts. WHO https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 10 Oct 2024;https:\/\/www.who.int\/en\/news-room\/fact-sheets\/detail\/hepatitis-c. Accessed 9 Apr 2024"},{"key":"6419_CR2","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1016\/j.jval.2022.01.004","volume":"25","author":"M Adee","year":"2022","unstructured":"Adee M et al (2022) Cost-Effectiveness of a Core Antigen-Based Rapid Diagnostic Test for Hepatitis C. Value Health 25:1107\u20131115. https:\/\/doi.org\/10.1016\/j.jval.2022.01.004","journal-title":"Value Health"},{"key":"6419_CR3","doi-asserted-by":"publisher","first-page":"1430","DOI":"10.1002\/hep.28473","volume":"63","author":"V Leroy","year":"2016","unstructured":"Leroy V et al (2016) Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+). Hepatology 63:1430\u20131441. https:\/\/doi.org\/10.1002\/hep.28473","journal-title":"Hepatology"},{"key":"6419_CR4","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1002\/hep.26371","volume":"58","author":"A Aghemo","year":"2013","unstructured":"Aghemo A, De Francesco R (2013) New horizons in hepatitis C antiviral therapy with direct-acting antivirals. Hepatology 58:428\u2013438. https:\/\/doi.org\/10.1002\/hep.26371","journal-title":"Hepatology"},{"key":"6419_CR5","doi-asserted-by":"publisher","unstructured":"Tsai WC et al (2023) Chronic Hepatitis C Virus Infection: An Ongoing Challenge in Screening and Treatment. Life (Basel) 13. https:\/\/doi.org\/10.3390\/life13101964","DOI":"10.3390\/life13101964"},{"key":"6419_CR6","doi-asserted-by":"publisher","unstructured":"Cox AL (2020) Challenges and Promise of a Hepatitis C Virus Vaccine. Cold Spring Harb Perspect Med 10. https:\/\/doi.org\/10.1101\/cshperspect.a036947","DOI":"10.1101\/cshperspect.a036947"},{"key":"6419_CR7","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1136\/gutjnl-2011-300620","volume":"61","author":"P Klenerman","year":"2012","unstructured":"Klenerman P, Thimme R (2012) T cell responses in hepatitis C: the good, the bad and the unconventional. Gut 61:1226\u20131234. https:\/\/doi.org\/10.1136\/gutjnl-2011-300620","journal-title":"Gut"},{"key":"6419_CR8","doi-asserted-by":"publisher","first-page":"2451","DOI":"10.1073\/pnas.88.6.2451","volume":"88","author":"QL Choo","year":"1991","unstructured":"Choo QL et al (1991) Genetic organization and diversity of the hepatitis C virus. Proc Natl Acad Sci U S A 88:2451\u20132455. https:\/\/doi.org\/10.1073\/pnas.88.6.2451","journal-title":"Proc Natl Acad Sci U S A"},{"key":"6419_CR9","doi-asserted-by":"publisher","first-page":"198","DOI":"10.1128\/JVI.69.1.198-205.1995","volume":"69","author":"R Bartenschlager","year":"1995","unstructured":"Bartenschlager R, Ahlborn-Laake L, Yasargil K, Mous J, Jacobsen H (1995) Substrate determinants for cleavage in cis and in trans by the hepatitis C virus NS3 proteinase. J Virol 69:198\u2013205. https:\/\/doi.org\/10.1128\/JVI.69.1.198-205.1995","journal-title":"J Virol"},{"key":"6419_CR10","doi-asserted-by":"publisher","first-page":"1385","DOI":"10.1128\/JVI.67.3.1385-1395.1993","volume":"67","author":"A Grakoui","year":"1993","unstructured":"Grakoui A, Wychowski C, Lin C, Feinstone SM, Rice CM (1993) Expression and identification of hepatitis C virus polyprotein cleavage products. J Virol 67:1385\u20131395. https:\/\/doi.org\/10.1128\/JVI.67.3.1385-1395.1993","journal-title":"J Virol"},{"key":"6419_CR11","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1038\/s41423-022-00897-8","volume":"19","author":"MO Mohsen","year":"2022","unstructured":"Mohsen MO, Bachmann MF (2022) Virus-like particle vaccinology, from bench to bedside. Cell Mol Immunol 19:993\u20131011. https:\/\/doi.org\/10.1038\/s41423-022-00897-8","journal-title":"Cell Mol Immunol"},{"key":"6419_CR12","doi-asserted-by":"publisher","first-page":"1332939","DOI":"10.3389\/fimmu.2024.1332939","volume":"15","author":"B Lu","year":"2024","unstructured":"Lu B et al (2024) The next-generation DNA vaccine platforms and delivery systems: advances, challenges and prospects. Front Immunol 15:1332939. https:\/\/doi.org\/10.3389\/fimmu.2024.1332939","journal-title":"Front Immunol"},{"key":"6419_CR13","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1080\/14760584.2024.2320327","volume":"23","author":"S Mir","year":"2024","unstructured":"Mir S, Mir M (2024) The mRNA vaccine, a swift warhead against a moving infectious disease target. Expert Rev Vaccines 23:336\u2013348. https:\/\/doi.org\/10.1080\/14760584.2024.2320327","journal-title":"Expert Rev Vaccines"},{"key":"6419_CR14","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12896-024-00935-5","volume":"25","author":"AA Ali","year":"2025","unstructured":"Ali AA et al (2025) Development of Virus-Like Particles (VLPs) for Hepatitis C Virus genotype 4: a novel approach for vaccine development in Egypt. BMC Biotechnol 25:8. https:\/\/doi.org\/10.1186\/s12896-024-00935-5","journal-title":"BMC Biotechnol"},{"key":"6419_CR15","doi-asserted-by":"publisher","first-page":"1234","DOI":"10.4254\/wjh.v13.i10.1234","volume":"13","author":"N Echeverria","year":"2021","unstructured":"Echeverria N et al (2021) In the era of rapid mRNA-based vaccines: Why is there no effective hepatitis C virus vaccine yet? World J Hepatol 13:1234\u20131268. https:\/\/doi.org\/10.4254\/wjh.v13.i10.1234","journal-title":"World J Hepatol"},{"key":"6419_CR16","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1586\/erv.11.188","volume":"11","author":"F Saade","year":"2012","unstructured":"Saade F, Petrovsky N (2012) Technologies for enhanced efficacy of DNA vaccines. Expert Rev Vaccines 11:189\u2013209. https:\/\/doi.org\/10.1586\/erv.11.188","journal-title":"Expert Rev Vaccines"},{"key":"6419_CR17","doi-asserted-by":"publisher","first-page":"168297","DOI":"10.1016\/j.jmb.2023.168297","volume":"435","author":"S Pagliari","year":"2023","unstructured":"Pagliari S, Dema B, Sanchez-Martinez A, Montalvo Zurbia-Flores G, Rollier CS (2023) DNA Vaccines: History, Molecular Mechanisms and Future Perspectives. J Mol Biol 435:168297. https:\/\/doi.org\/10.1016\/j.jmb.2023.168297","journal-title":"J Mol Biol"},{"key":"6419_CR18","doi-asserted-by":"publisher","unstructured":"Costa GL, Sautto GA (2024) Exploring T-Cell Immunity to Hepatitis C Virus: Insights from Different Vaccine and Antigen Presentation Strategies. Vaccines (Basel) 12. https:\/\/doi.org\/10.3390\/vaccines12080890","DOI":"10.3390\/vaccines12080890"},{"key":"6419_CR19","doi-asserted-by":"publisher","first-page":"5859","DOI":"10.1128\/JVI.69.9.5859-5863.1995","volume":"69","author":"LM Lagging","year":"1995","unstructured":"Lagging LM et al (1995) Immune responses to plasmid DNA encoding the hepatitis C virus core protein. J Virol 69:5859\u20135863. https:\/\/doi.org\/10.1128\/JVI.69.9.5859-5863.1995","journal-title":"J Virol"},{"key":"6419_CR20","doi-asserted-by":"publisher","first-page":"3160","DOI":"10.1016\/s0264-410x(99)00130-9","volume":"17","author":"GJ Hu","year":"1999","unstructured":"Hu GJ, Wang RY, Han DS, Alter HJ, Shih JW (1999) Characterization of the humoral and cellular immune responses against hepatitis C virus core induced by DNA-based immunization. Vaccine 17:3160\u20133170. https:\/\/doi.org\/10.1016\/s0264-410x(99)00130-9","journal-title":"Vaccine"},{"key":"6419_CR21","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1002\/jmv.2148","volume":"66","author":"P Ou-Yang","year":"2002","unstructured":"Ou-Yang P, Hwang LH, Tao MH, Chiang BL, Chen DS (2002) Co-delivery of GM-CSF gene enhances the immune responses of hepatitis C viral core protein-expressing DNA vaccine: role of dendritic cells. J Med Virol 66:320\u2013328. https:\/\/doi.org\/10.1002\/jmv.2148","journal-title":"J Med Virol"},{"key":"6419_CR22","doi-asserted-by":"publisher","first-page":"105266","DOI":"10.1016\/j.antiviral.2022.105266","volume":"199","author":"K Yato","year":"2022","unstructured":"Yato K et al (2022) Induction of neutralizing antibodies against hepatitis C virus by a subviral particle-based DNA vaccine. Antiviral Res 199:105266. https:\/\/doi.org\/10.1016\/j.antiviral.2022.105266","journal-title":"Antiviral Res"},{"key":"6419_CR23","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3389\/fimmu.2019.01145","volume":"10","author":"MG Masavuli","year":"2019","unstructured":"Masavuli MG et al (2019) A Hepatitis C Virus DNA Vaccine Encoding a Secreted, Oligomerized Form of Envelope Proteins Is Highly Immunogenic and Elicits Neutralizing Antibodies in Vaccinated Mice. Front Immunol 10:1145. https:\/\/doi.org\/10.3389\/fimmu.2019.01145","journal-title":"Front Immunol"},{"key":"6419_CR24","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1002\/jmv.24277","volume":"87","author":"W Sun","year":"2015","unstructured":"Sun W et al (2015) Enhancement of immune response to a hepatitis C virus E2 DNA vaccine by an immunoglobulin Fc fusion tag. J Med Virol 87:2090\u20132097. https:\/\/doi.org\/10.1002\/jmv.24277","journal-title":"J Med Virol"},{"key":"6419_CR25","first-page":"295","volume":"40","author":"S Shao","year":"2011","unstructured":"Shao S, Zhou H, Tong Y, Ren Y, Chen Z (2011) Study of neutralization antibodie induced by DNA vaccine of HCV envelope protein 2 in mice. Wei Sheng Yan Jiu=J Hyg Res 40:295\u2013298 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21695897","journal-title":"Wei Sheng Yan Jiu=J Hyg Res"},{"key":"6419_CR26","first-page":"53","volume":"24","author":"B Wen","year":"2010","unstructured":"Wen B et al (2010) Construction and evaluation of hepatitis C virus (HCV) DNA vaccine containing E2-gAD fusion gene. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 24:53\u201355 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/20848852","journal-title":"Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi"},{"key":"6419_CR27","doi-asserted-by":"publisher","first-page":"1764","DOI":"10.1016\/j.bbagen.2015.08.007","volume":"1860","author":"Y Ren","year":"2016","unstructured":"Ren Y et al (2016) N-glycosylation-mutated HCV envelope glycoprotein complex enhances antigen-presenting activity and cellular and neutralizing antibody responses. Biochim Biophys Acta 1860:1764\u20131775. https:\/\/doi.org\/10.1016\/j.bbagen.2015.08.007","journal-title":"Biochim Biophys Acta"},{"key":"6419_CR28","doi-asserted-by":"publisher","first-page":"6572","DOI":"10.1016\/j.vaccine.2007.07.003","volume":"25","author":"M Liu","year":"2007","unstructured":"Liu M et al (2007) Deletion of N-glycosylation sites of hepatitis C virus envelope protein E1 enhances specific cellular and humoral immune responses. Vaccine 25:6572\u20136580. https:\/\/doi.org\/10.1016\/j.vaccine.2007.07.003","journal-title":"Vaccine"},{"key":"6419_CR29","doi-asserted-by":"publisher","first-page":"1","DOI":"10.6091\/ibj.1231.2013","volume":"18","author":"Z Gorzin","year":"2014","unstructured":"Gorzin Z et al (2014) Immunogenicity evaluation of a DNA vaccine expressing the hepatitis C virus non-structural protein 2 gene in C57BL\/6 mice. Iran Biomed J 18:1\u20137. https:\/\/doi.org\/10.6091\/ibj.1231.2013","journal-title":"Iran Biomed J"},{"key":"6419_CR30","doi-asserted-by":"publisher","unstructured":"Gummow J et al (2020) Safety Profile of a Multi-Antigenic DNA Vaccine Against Hepatitis C Virus. Vaccines (Basel) 8. https:\/\/doi.org\/10.3390\/vaccines8010053","DOI":"10.3390\/vaccines8010053"},{"key":"6419_CR31","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.1002\/iub.2109","volume":"71","author":"MH Pouriayevali","year":"2019","unstructured":"Pouriayevali MH et al (2019) Listeriolysin O immunogenetic adjuvant enhanced potency of hepatitis C virus NS3 DNA vaccine. IUBMB Life 71:1645\u20131652. https:\/\/doi.org\/10.1002\/iub.2109","journal-title":"IUBMB Life"},{"key":"6419_CR32","doi-asserted-by":"publisher","first-page":"43531","DOI":"10.1038\/srep43531","volume":"7","author":"H Lee","year":"2017","unstructured":"Lee H et al (2017) Preclinical evaluation of multi antigenic HCV DNA vaccine for the prevention of Hepatitis C virus infection. Sci Rep 7:43531. https:\/\/doi.org\/10.1038\/srep43531","journal-title":"Sci Rep"},{"key":"6419_CR33","doi-asserted-by":"publisher","first-page":"7991","DOI":"10.1128\/JVI.00803-15","volume":"89","author":"J Gummow","year":"2015","unstructured":"Gummow J et al (2015) A Multiantigenic DNA Vaccine That Induces Broad Hepatitis C Virus-Specific T-Cell Responses in Mice. J Virol 89:7991\u20138002. https:\/\/doi.org\/10.1128\/JVI.00803-15","journal-title":"J Virol"},{"key":"6419_CR34","doi-asserted-by":"publisher","first-page":"e98877","DOI":"10.1371\/journal.pone.0098877","volume":"9","author":"SL Ratnoglik","year":"2014","unstructured":"Ratnoglik SL et al (2014) Induction of cell-mediated immune responses in mice by DNA vaccines that express hepatitis C virus NS3 mutants lacking serine protease and NTPase\/RNA helicase activities. PLoS One 9:e98877. https:\/\/doi.org\/10.1371\/journal.pone.0098877","journal-title":"PLoS One"},{"key":"6419_CR35","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s12250-013-3291-z","volume":"28","author":"M Naderi","year":"2013","unstructured":"Naderi M et al (2013) Interleukin-12 as a genetic adjuvant enhances hepatitis C virus NS3 DNA vaccine immunogenicity. Virol Sin 28:167\u2013173. https:\/\/doi.org\/10.1007\/s12250-013-3291-z","journal-title":"Virol Sin"},{"key":"6419_CR36","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1038\/mt.2011.188","volume":"20","author":"KA Lang Kuhs","year":"2012","unstructured":"Lang Kuhs KA et al (2012) Hepatitis C virus NS3\/NS4A DNA vaccine induces multiepitope T cell responses in rhesus macaques mimicking human immune responses [corrected]. Mol Ther 20:669\u2013678. https:\/\/doi.org\/10.1038\/mt.2011.188","journal-title":"Mol Ther"},{"key":"6419_CR37","doi-asserted-by":"publisher","first-page":"7462","DOI":"10.4049\/jimmunol.177.10.7462","volume":"177","author":"S Capone","year":"2006","unstructured":"Capone S et al (2006) Modulation of the immune response induced by gene electrotransfer of a hepatitis C virus DNA vaccine in nonhuman primates. J Immunol 177:7462\u20137471. https:\/\/doi.org\/10.4049\/jimmunol.177.10.7462","journal-title":"J Immunol"},{"key":"6419_CR38","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.4049\/jimmunol.1201497","volume":"190","author":"F Holmstrom","year":"2013","unstructured":"Holmstrom F et al (2013) A synthetic codon-optimized hepatitis C virus nonstructural 5A DNA vaccine primes polyfunctional CD8+ T cell responses in wild-type and NS5A-transgenic mice. J Immunol 190:1113\u20131124. https:\/\/doi.org\/10.4049\/jimmunol.1201497","journal-title":"J Immunol"},{"key":"6419_CR39","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/s12985-021-01716-8","volume":"18","author":"A Shayeghpour","year":"2021","unstructured":"Shayeghpour A et al (2021) Hepatitis C virus DNA vaccines: a systematic review. Virol J 18:248. https:\/\/doi.org\/10.1186\/s12985-021-01716-8","journal-title":"Virol J"},{"key":"6419_CR40","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1158\/1940-6207.CAPR-22-0217","volume":"16","author":"JM Jacobson","year":"2023","unstructured":"Jacobson JM et al (2023) Phase I Trial of a Therapeutic DNA Vaccine for Preventing Hepatocellular Carcinoma from Chronic Hepatitis C Virus (HCV) Infection. Cancer Prev Res (Phila) 16:163\u2013173. https:\/\/doi.org\/10.1158\/1940-6207.CAPR-22-0217","journal-title":"Cancer Prev Res (Phila)"},{"key":"6419_CR41","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.jhep.2020.02.009","volume":"73","author":"JW Han","year":"2020","unstructured":"Han JW et al (2020) IFNL3-adjuvanted HCV DNA vaccine reduces regulatory T cell frequency and increases virus-specific T cell responses. J Hepatol 73:72\u201383. https:\/\/doi.org\/10.1016\/j.jhep.2020.02.009","journal-title":"J Hepatol"},{"key":"6419_CR42","doi-asserted-by":"publisher","first-page":"110307","DOI":"10.1016\/j.virol.2024.110307","volume":"602","author":"AA Ali","year":"2025","unstructured":"Ali AA, Tabll AA (2025) Unlocking potential: Virus-like particles as a promising strategy for effective HCV vaccine development. Virology 602:110307. https:\/\/doi.org\/10.1016\/j.virol.2024.110307","journal-title":"Virology"},{"key":"6419_CR43","first-page":"199","volume-title":"Interaction of Hepatitis C Virus Polymerase with Host Cell Proteins, in Department of Biosciences","author":"AA Ali","year":"2009","unstructured":"Ali AA (2009) Interaction of Hepatitis C Virus Polymerase with Host Cell Proteins, in Department of Biosciences. Durham University: Online, p 199"},{"key":"6419_CR44","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jviromet.2016.10.005","volume":"238","author":"MK Monninger","year":"2016","unstructured":"Monninger MK et al (2016) Preparation of viral samples within biocontainment for ultrastructural analysis: Utilization of an innovative processing capsule for negative staining. J Virol Methods 238:70\u201376. https:\/\/doi.org\/10.1016\/j.jviromet.2016.10.005","journal-title":"J Virol Methods"},{"key":"6419_CR45","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1089\/vim.2015.0085","volume":"29","author":"MA Behzadi","year":"2016","unstructured":"Behzadi MA et al (2016) Immunization with a Recombinant Expression Vector Encoding NS3\/NS4A of Hepatitis C Virus Genotype 3a Elicits Cell-Mediated Immune Responses in C57BL\/6 Mice. Viral Immunol 29:138\u2013147. https:\/\/doi.org\/10.1089\/vim.2015.0085","journal-title":"Viral Immunol"},{"key":"6419_CR46","doi-asserted-by":"publisher","first-page":"3263","DOI":"10.1016\/s0264-410x(02)00304-3","volume":"20","author":"X Ma","year":"2002","unstructured":"Ma X et al (2002) DNA-based vaccination against hepatitis C virus (HCV): effect of expressing different forms of HCV E2 protein and use of CpG-optimized vectors in mice. Vaccine 20:3263\u20133271. https:\/\/doi.org\/10.1016\/s0264-410x(02)00304-3","journal-title":"Vaccine"},{"key":"6419_CR47","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1007\/s11262-009-0417-3","volume":"40","author":"A Arashkia","year":"2010","unstructured":"Arashkia A, Roohvand F, Memarnejadian A, Aghasadeghi MR, Rafati S (2010) Construction of HCV-polytope vaccine candidates harbouring immune-enhancer sequences and primary evaluation of their immunogenicity in BALB\/c mice. Virus Genes 40:44\u201352. https:\/\/doi.org\/10.1007\/s11262-009-0417-3","journal-title":"Virus Genes"},{"key":"6419_CR48","doi-asserted-by":"publisher","unstructured":"Tabll AA et al (2024) Future Prospects, Approaches, and the Government's Role in the Development of a Hepatitis C Virus Vaccine. Pathogens 13. https:\/\/doi.org\/10.3390\/pathogens13010038","DOI":"10.3390\/pathogens13010038"},{"key":"6419_CR49","doi-asserted-by":"publisher","unstructured":"Garbuglia AR, Pauciullo S, Zulian V, Del Porto P (2024) Update on Hepatitis C Vaccine: Results and Challenges. Viruses 16. https:\/\/doi.org\/10.3390\/v16081337","DOI":"10.3390\/v16081337"},{"key":"6419_CR50","doi-asserted-by":"publisher","first-page":"675","DOI":"10.1016\/s0264-410x(99)00270-4","volume":"18","author":"Y Nishimura","year":"1999","unstructured":"Nishimura Y et al (1999) A single immunization with a plasmid encoding hepatitis C virus (HCV) structural proteins under the elongation factor 1-alpha promoter elicits HCV-specific cytotoxic T-lymphocytes (CTL). Vaccine 18:675\u2013680. https:\/\/doi.org\/10.1016\/s0264-410x(99)00270-4","journal-title":"Vaccine"},{"key":"6419_CR51","doi-asserted-by":"publisher","first-page":"41","DOI":"10.4067\/S0716-97602009000100005","volume":"42","author":"N Acosta-Rivero","year":"2009","unstructured":"Acosta-Rivero N et al (2009) Recombinant in vitro assembled hepatitis C virus core particles induce strong specific immunity enhanced by formulation with an oil-based adjuvant. Biol Res 42:41\u201356. https:\/\/doi.org\/10.4067\/S0716-97602009000100005","journal-title":"Biol Res"},{"key":"6419_CR52","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1016\/j.bbrc.2006.12.232","volume":"354","author":"F Roohvand","year":"2007","unstructured":"Roohvand F, Aghasadeghi MR, Sadat SM, Budkowska A, Khabiri AR (2007) HCV core protein immunization with Montanide\/CpG elicits strong Th1\/Th2 and long-lived CTL responses. Biochem Biophys Res Commun 354:641\u2013649. https:\/\/doi.org\/10.1016\/j.bbrc.2006.12.232","journal-title":"Biochem Biophys Res Commun"},{"key":"6419_CR53","doi-asserted-by":"publisher","first-page":"910","DOI":"10.3389\/fimmu.2018.00910","volume":"9","author":"M Lavie","year":"2018","unstructured":"Lavie M, Hanoulle X, Dubuisson J (2018) Glycan Shielding and Modulation of Hepatitis C Virus Neutralizing Antibodies. Front Immunol 9:910. https:\/\/doi.org\/10.3389\/fimmu.2018.00910","journal-title":"Front Immunol"},{"key":"6419_CR54","doi-asserted-by":"publisher","unstructured":"Pierce BG et al (2024) Hepatitis C Virus E1E2 Structure, Diversity, and Implications for Vaccine Development. Viruses 16. https:\/\/doi.org\/10.3390\/v16050803","DOI":"10.3390\/v16050803"},{"key":"6419_CR55","doi-asserted-by":"publisher","unstructured":"Yechezkel I, Law M, Tzarum N (2021) From Structural Studies to HCV Vaccine Design. Viruses 13. https:\/\/doi.org\/10.3390\/v13050833","DOI":"10.3390\/v13050833"},{"key":"6419_CR56","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.3390\/v6031149","volume":"6","author":"G Vieyres","year":"2014","unstructured":"Vieyres G, Dubuisson J, Pietschmann T (2014) Incorporation of hepatitis C virus E1 and E2 glycoproteins: the keystones on a peculiar virion. Viruses 6:1149\u20131187. https:\/\/doi.org\/10.3390\/v6031149","journal-title":"Viruses"},{"key":"6419_CR57","doi-asserted-by":"publisher","first-page":"474","DOI":"10.3892\/etm.2022.11401","volume":"24","author":"Q Zhao","year":"2022","unstructured":"Zhao Q et al (2022) Production and immunogenicity of different prophylactic vaccines for hepatitis C virus (Review). Exp Ther Med 24:474. https:\/\/doi.org\/10.3892\/etm.2022.11401","journal-title":"Exp Ther Med"},{"key":"6419_CR58","doi-asserted-by":"publisher","first-page":"111742","DOI":"10.1016\/j.mad.2022.111742","volume":"209","author":"K Li","year":"2023","unstructured":"Li K et al (2023) B cells from old mice induce the generation of inflammatory T cells through metabolic pathways. Mech Ageing Dev 209:111742. https:\/\/doi.org\/10.1016\/j.mad.2022.111742","journal-title":"Mech Ageing Dev"},{"key":"6419_CR59","doi-asserted-by":"publisher","first-page":"e1012615","DOI":"10.1371\/journal.ppat.1012615","volume":"20","author":"J Lopez-Scarim","year":"2024","unstructured":"Lopez-Scarim J, Mendoza D, Nambiar SM, Billerbeck E (2024) CD4+ T cell help during early acute hepacivirus infection is critical for viral clearance and the generation of a liver-homing CD103+CD49a+ effector CD8+ T cell subset. PLoS Pathog 20:e1012615. https:\/\/doi.org\/10.1371\/journal.ppat.1012615","journal-title":"PLoS Pathog"},{"key":"6419_CR60","first-page":"44","volume":"27","author":"X Yin","year":"2011","unstructured":"Yin X et al (2011) Enhancement of the immune response in mice with a noval HCV DNA vaccine targeting NS3 to dendritic cells. Bing Du Xue Bao 27:44\u201349 https:\/\/www.ncbi.nlm.nih.gov\/pubmed\/21462505","journal-title":"Bing Du Xue Bao"},{"key":"6419_CR61","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1016\/s0016-5085(97)70146-x","volume":"112","author":"T Saito","year":"1997","unstructured":"Saito T et al (1997) Plasmid DNA-based immunization for hepatitis C virus structural proteins: immune responses in mice. Gastroenterology 112:1321\u20131330. https:\/\/doi.org\/10.1016\/s0016-5085(97)70146-x","journal-title":"Gastroenterology"},{"key":"6419_CR62","doi-asserted-by":"publisher","unstructured":"Marin MQ et al (2019) Potent Anti-hepatitis C Virus (HCV) T Cell Immune Responses Induced in Mice Vaccinated with DNA-Launched RNA Replicons and Modified Vaccinia Virus Ankara-HCV. J Virol 93. https:\/\/doi.org\/10.1128\/JVI.00055-19","DOI":"10.1128\/JVI.00055-19"},{"key":"6419_CR63","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1038\/gt.2016.55","volume":"23","author":"CS Rollier","year":"2016","unstructured":"Rollier CS et al (2016) T- and B-cell responses to multivalent prime-boost DNA and viral vectored vaccine combinations against hepatitis C virus in non-human primates. Gene Ther 23:753\u2013759. https:\/\/doi.org\/10.1038\/gt.2016.55","journal-title":"Gene Ther"},{"key":"6419_CR64","doi-asserted-by":"publisher","first-page":"2085","DOI":"10.1016\/j.vaccine.2009.02.003","volume":"27","author":"Y Deng","year":"2009","unstructured":"Deng Y et al (2009) A recombinant DNA and vaccinia virus prime-boost regimen induces potent long-term T-cell responses to HCV in BALB\/c mice. Vaccine 27:2085\u20132088. https:\/\/doi.org\/10.1016\/j.vaccine.2009.02.003","journal-title":"Vaccine"},{"key":"6419_CR65","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1042\/BA200301129","volume":"39","author":"S Duenas-Carrera","year":"2004","unstructured":"Duenas-Carrera S et al (2004) Immunization with a DNA vaccine encoding the hepatitis-C-virus structural antigens elicits a specific immune response against the capsid and envelope proteins in rabbits and Macaca irus (crab-eating macaque monkeys). Biotechnol Appl Biochem 39:249\u2013255. https:\/\/doi.org\/10.1042\/BA200301129","journal-title":"Biotechnol Appl Biochem"},{"key":"6419_CR66","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1042\/ba20010089","volume":"35","author":"S Duenas-Carrera","year":"2002","unstructured":"Duenas-Carrera S et al (2002) Enhancement of the immune response generated against hepatitis C virus envelope proteins after DNA vaccination with polyprotein-encoding plasmids. Biotechnol Appl Biochem 35:205\u2013212. https:\/\/doi.org\/10.1042\/ba20010089","journal-title":"Biotechnol Appl Biochem"},{"key":"6419_CR67","doi-asserted-by":"publisher","first-page":"12121","DOI":"10.1128\/JVI.75.24.12121-12127.2001","volume":"75","author":"J Satoi","year":"2001","unstructured":"Satoi J et al (2001) Genetic immunization of wild-type and hepatitis C virus transgenic mice reveals a hierarchy of cellular immune response and tolerance induction against hepatitis C virus structural proteins. J Virol 75:12121\u201312127. https:\/\/doi.org\/10.1128\/JVI.75.24.12121-12127.2001","journal-title":"J Virol"},{"key":"6419_CR68","doi-asserted-by":"publisher","first-page":"5968","DOI":"10.1016\/j.vaccine.2013.10.037","volume":"31","author":"T Wada","year":"2013","unstructured":"Wada T, Kohara M, Yasutomi Y (2013) DNA vaccine expressing the non-structural proteins of hepatitis C virus diminishes the expression of HCV proteins in a mouse model. Vaccine 31:5968\u20135974. https:\/\/doi.org\/10.1016\/j.vaccine.2013.10.037","journal-title":"Vaccine"}],"container-title":["Archives of Virology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-025-06419-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00705-025-06419-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00705-025-06419-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T17:04:52Z","timestamp":1764176692000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00705-025-06419-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,10]]},"references-count":68,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["6419"],"URL":"https:\/\/doi.org\/10.1007\/s00705-025-06419-x","relation":{},"ISSN":["0304-8608","1432-8798"],"issn-type":[{"value":"0304-8608","type":"print"},{"value":"1432-8798","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,10]]},"assertion":[{"value":"9 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All animal experiments conducted in this study were carried out in strict accordance with the guidelines and regulations for the care and use of laboratory animals. The experimental protocol for the DNA vaccination study in mice was reviewed and approved by the Medical Research Ethics Committee at the National Research Centre, Cairo, Egypt (approval number 1-1-1-12). The procedures followed ensured minimal discomfort and stress to the animals, in compliance with the internationally accepted standards. This study was reported in accordance with the ARRIVE guidelines (Animal Research: Reporting of In Vivo Experiments) (\n                      \n                      ).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors declare that they have no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"244"}}